PDCD1 and cancer: Immune checkpoint inhibitors (ICIs) have shown dramatic improvement in clinical outcomes compared with standard therapy for a range of cancer types in recent years, it enhances antitumor immunity by targeting intrinsic down regulators of immunity, such as programmed cell death 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1) (1).